SOLICITATION NOTICE
65 -- Human Spheroid-Qualified Hepatocytes
- Notice Date
- 7/22/2023 1:38:30 PM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- 75N95023Q00508
- Response Due
- 7/27/2023 6:00:00 AM
- Archive Date
- 08/03/2023
- Point of Contact
- Kimberly Espinosa, Phone: 301-827-3546
- E-Mail Address
-
kimberly.espinosa@nih.gov
(kimberly.espinosa@nih.gov)
- Description
- THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing full and open competition for Human Spheroid-Qualified Hepatocytes from Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008. This acquisition is conducted as non-competitive for a commercial item or service and is conducted pursuant to FAR 13.106-1(b)(1). The rationale for the brand-name justification: Human Spheroid-Qualified Hepatocytes from Life Technologies were used to optimize viral infection for this project. Since the assay was optimized using these Hepatocytes from Life Technologies and these Hepatocytes were previously used for this project, the Hepatocytes required in this acquisition must also come from Life Technologies to ensure consistent data and the continuity of science. Introducing cells from another vendor may introduce variables and skew the data. Therefore, the required Hepatocytes must come from Life Technologies and this solicitation is restricted to Life Technologies and its authorized resellers. The National Center for Advancing Translational Sciences (NCATS), within the National Institutes of Health (NIH), requires 50 vials of cryopreserved, primary human liver cells (non-fetal) to support the Antiviral Program for Pandemics (APP) program. NCATS works to identify direct acting antivirals towards viruses and for development of microphysiological systems (MPS) for second-line drug screening. See attached Combined Synopsis / Solicitation and attachments for complete requirement details.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/cde7072ed085410e89881b3c034b9a8c/view)
- Record
- SN06759654-F 20230724/230722230043 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |